Many PsA Patients Who Begin DMARD Therapy Switch Treatments
A high percentage of PsA patients newly initiated on a nonbiologic or biologic oral disease-modifying antirheumatic drugs (DMARDs) switch treatments after a short period of time, according to a recent study.
The researchers sought to clarify treatment changes such as discontinuation, switching, and therapy add-on following the start of DMARD therapy by evaluating 1698 and 3263 patients who were initiated on nonbiologic DMARDs and biologic DMARDs, respectively.
In the nonbiologic DMARD group, 69% of patients had ≥1 therapy change over a year, with a median time of 85 days to first therapy change. Among the patients who changed therapies, 83% discontinued therapy; 29% switched therapies, with 64% of those patients changing to a biologic DMARD; and 25% had a therapy add-on, with 76% of those patients adding a biologic DMARD.
In the biologic DMARD group, 46% had ≥1 therapy change with a median time of 110 days to first therapy change. Among the patients who changed therapies, 100% discontinued; 25% switched therapies, with 92% of those patients changing to another biologic DMARD; and 7% of patients added a nonbiologic DMARD.
“This study suggests that PsA patients newly initiated on a nonbiologic/biologic DMARD do not remain on the index treatment for a long period of time,” the authors concluded. “A better understanding of factors related to these early treatment changes in PsA patients is needed.” SPT
Articles in this issue
almost 11 years ago
Article
Recently Approved Crohn's Disease Treatment Shows No Added Benefit over Competitoralmost 11 years ago
Article
Investigational Crohn's Disease Drug Shows Favorable Results in Clinical Trialalmost 11 years ago
Article
Strategies for Protecting Pharmacists from Chemotherapeutic Medication Contamination During Compoundingalmost 11 years ago
Article
The Accreditation Difference: Excellence in Specialty Pharmacy Patient Carealmost 11 years ago
Article
The Specialty Pharmacy's Role in Ensuring the Effectiveness of New Hepatitis C Drugsalmost 11 years ago
Article
Study Will Evaluate Promising Ulcerative Colitis Treatment in Crohn's Disease PatientsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
Evaluation of Pharmacist-Driven Penicillin Allergy ReconciliationSeptember 17th 2025
Pharmacists Can Apply Their Expertise to the Medical Psilocybin ActSeptember 16th 2025
From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy ResearchSeptember 15th 2025
